A half-life measured in weeks—not hours 1

HEMLIBRA has a half-life of 4 weeks (646 hours), with sustained therapeutic drug levels across dosing options

“Regardless of which regimen, all of the levels…are in the therapeutic range and fairly flat and even.” 2

—Dr Guy Young, MD, Keck School of Medicine of the University of Southern California

Sustained mean (±SD) trough plasma concentrations of HEMLIBRA at steady-state were 51.2±15.2 μg/mL, 46.9±14.8 μg/mL, and 38.5±14.2 μg/mL with maintenance dosing of 1.5 mg/kg QW, 3 mg/kg Q2W, and 6 mg/kg Q4W, respectively.

  • Steady-state drug concentrations were achieved after the 4 QW loading doses and sustained with QW, Q2W, and Q4W maintenance doses
  • The steady-state plasma trough concentrations of HEMLIBRA were comparable in adult and pediatric patients older than 6 months at equivalent weight-based doses
    • Lower concentrations of HEMLIBRA were predicted in pediatric patients less than 6 months old

FVIII=factor VIII; QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks; SD=standard deviation.

Zero Treated Bleeds Data

See the HEMLIBRA zero treated bleeds data for patients with and without FVIII inhibitors